Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy

•Transient potential receptor melastatin-2 is expressed in myeloid cells.•Transient potential receptor melastatin-2 has been reported to modulate NF-κB.•NF-κB is required for MLL-AF9 and BCR-ABL/NUP98-HOXA9 acute myeloid leukemia-initiating cells.•Nevertheless, loss of Trpm2 only minimally affects leukemogenesis in these models.•Loss of Trpm2 does not potentiate standard acute myeloid leukemia chemotherapy. Transient potential receptor...